Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tirofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 0.95 |
| ▸ | ITGA2B known ✓ | P08514 | 20/20 | 0.95 |
| ▸ | ITGAV | P06756 | 2/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirofiban SCHEMBL140366 | 0.99 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL28858023 | 0.98 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41325 | 0.97 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL7388934 | 0.97 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL618214 | 0.97 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL17721319 | 0.97 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL3685 | 0.97 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL155170 | 0.96 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41327 | 0.96 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13873863 | 0.88 | ITGB3 (0.83) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3959 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| EP-4705465-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| CN-119438403-A | Detection method of 5-hydroxymethylfurfural in tirofiban hydrochloride injection compatibility test | 山东新时代药业有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119335093-A | Method for measuring sodium chloride content in tirofiban hydrochloride sodium chloride injection | 南京桦冠生物技术有限公司 | 2025-01-21 | — | — | CN | claimed |
| WO-2024240058-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-11-28 | — | — | WO | claimed |
| CN-118647417-A | Directional and time release of drugs from medical devices | 纳米疗法私人有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-115894306-B | Preparation method of N-N-butyl sulfonyl-L-tyrosine methyl ester | 武汉武药科技有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | claimed |
| CN-115181058-B | Composition and quality control method thereof | 武汉武药科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20020107473-A1 | APPARATUS FOR EMERGENCY TREATMENT OF PATIENTS EXPERIENCING A THROMBOTIC VASCULAR OCCLUSION | BOND GEOFFREY (US) | 2002-08-08 | — | — | US | claimed |
| US-6398772-B1 | ADMINISTERING AGGRASTAT OR INTEGRILIN; AND ULTRASONICALLY RADIATING SAID VASCULAR OCCLUSION AND SAID ACTIVE AGENT IN ORDER TO SHORTEN ONSET AND ENHANCE EFFECTIVENESS OF LYSING ACTION OF SAID ACTIVE AGENT. | CORAJE, INC. | 2002-06-04 | — | — | US | claimed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | claimed |
| WO-2002019935-A1 | METHOD AND SYSTEM FOR ANTICOAGULANT DOSE REVISION | THE RXFILES CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1169080-A1 | METHOD AND APPARATUS FOR EMERGENCY TREATMENT OF A PATIENT EXPERIENCING A THROMBOTIC VASCULAR OCCLUSION | Transon, LLC (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2001092283-A2 | COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000057946-A1 | METHOD AND APPARATUS FOR EMERGENCY TREATMENT OF A PATIENT EXPERIENCING A THROMBOTIC VASCULAR OCCLUSION | TRANSON, LLC (US) | 2000-10-05 | — | — | WO | claimed |